Public inquiry · Parliamentary scrutiny

Parliamentary activity

Infected Blood Inquiry. Read indexed debates, questions, statements and early day motions, with links to the original parliamentary records.

394 indexed mentions for this inquiry Earliest recorded mention: 15 March 1990

Parliamentary mentions

4 matching mentions · newest first

Blood Transfusions

Written Question House of Lords
Earl Howe · Conservative Answering body: Department of Health and Social Care
Parliamentary excerpt

To ask His Majesty's Government, further to the recommendations in the Infected Blood Inquiry report, what assessment they have made of the safety and efficacy of modern plasma-derived therapies.

Government answer

Answering body: Department of Health and Social Care

The Government is considering Sir Brian Langstaff’s recommendations, including recommendation 9 that relates to the use of alternatives to plasma-derived medicines. We will provide an update to Parliament on the progress we are making by the end of the year, as the Inquiry recommends.

In April 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) reviewed the latest scientific evidence available on the safety of donor plasma from the United Kingdom and was able to lift the ban on its use for immunoglobulin-based medicines; the ban had been in place since the mid-1990s due to concerns about over the potential spread of variant Creutzfeldt-Jakob (vCJD) disease. This was followed by a review of and lifting of the ban on albumins, also derived from UK donor plasma.

Both immunoglobulin and albumin are critical medicines for the National Health Service, with approximately 17,000 patients in England relying on immunoglobulins each year but these products are in short supply globally. Following the MHRA view that UK plasma is safe, the Department set up the Plasma for Medicines programme to increase our self-sufficiency and to protect vulnerable patients from the risk of global supply shocks. The first UK donor plasma was shipped for manufacture into medicines in August 2024 and these will be available to NHS patients from January 2025.

Original parliamentary record

Blood Diseases: Medical Treatments

Written Question House of Lords
Earl Howe · Conservative Answering body: Department of Health and Social Care
Parliamentary excerpt

To ask His Majesty's Government how they interpret the phrase "where clinically appropriate" in recommendation 9(e) of the Infected Blood Inquiry report, and how this will preserve patient choice and clinical judgement based on the latest clinical evidence.

Government answer

Answering body: Department of Health and Social Care

I recognise that the findings of the inquiry’s final report are deeply shocking, and the Government is committed to acting on the findings of the Infected Blood Inquiry.

The Government is considering Sir Brian Langstaff’s recommendations, and will provide an update to Parliament on the progress we are making to respond to the inquiry’s recommendations by the end of the year, as the inquiry recommends.

Original parliamentary record

Medicines and Healthcare products Regulatory Agency

Written Question House of Lords
Earl Howe · Conservative Answering body: Department of Health and Social Care
Parliamentary excerpt

To ask His Majesty's Government what assessment they have made of the implications of the recommendations in the Infected Blood Inquiry report for the MHRA as regulator of medicines in the UK.

Government answer

Answering body: Department of Health and Social Care

I recognise that the findings of the inquiry’s final report are deeply shocking, and the Government is committed to acting on the findings of the Infected Blood Inquiry.

The Government is considering Sir Brian Langstaff’s recommendations, and will provide an update to Parliament on the progress we are making to respond to the inquiry’s recommendations by the end of the year, as the inquiry recommends.

Original parliamentary record

Blood Diseases: Health Services

Written Question House of Lords
Earl Howe · Conservative Answering body: Department of Health and Social Care
Parliamentary excerpt

To ask His Majesty's Government how they intend to implement recommendation 9(e) of the Infected Blood Inquiry report while maintaining consistency with existing NHS England commissioning guidelines, continuing to improve standards of care and quality of life, and promoting confidence in the safety and efficacy of all licensed medicines for people with rare bleeding disorders.

Government answer

Answering body: Department of Health and Social Care

I recognise that the findings of the inquiry’s final report are deeply shocking, and the Government is committed to acting on the findings of the Infected Blood Inquiry.

The Government is considering Sir Brian Langstaff’s recommendations, and will provide an update to Parliament on the progress we are making to respond to the inquiry’s recommendations by the end of the year, as the inquiry recommends.

Original parliamentary record